Published in Semin Oncol on December 01, 2013
Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group. J Clin Oncol (2015) 1.41
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia (2015) 1.16
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood (2016) 1.05
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol (2015) 0.90
Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature. Ann Surg Oncol (2015) 0.88
Therapy-related myeloid neoplasms - what have we learned so far? World J Stem Cells (2016) 0.87
Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2016) 0.85
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer (2016) 0.83
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol (2016) 0.83
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther (2017) 0.80
Blood disorders typically associated with renal transplantation. Front Cell Dev Biol (2015) 0.77
Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries. Sci Rep (2016) 0.75
Autologous hematopoietic stem cell transplantation in lymphoma patients is associated with a decrease in the double strand break repair capacity of peripheral blood lymphocytes. PLoS One (2017) 0.75
Study of clinical, haematological and cytogenetic profile of patients with acute erythroid leukaemia. Ecancermedicalscience (2017) 0.75
Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine. Oncotarget (2016) 0.75
A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Exp Hematol Oncol (2016) 0.75
Therapy-Associated Myeloid Dysplasia in a Long-Surviving Patient with Pancreatic Cancer. Cureus (2016) 0.75
Structure and function of telomeres. Nature (1991) 14.82
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell (1993) 13.54
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
The World Health Organization (WHO) classification of the myeloid neoplasms. Blood (2002) 10.87
Glutathione transferases. Annu Rev Pharmacol Toxicol (2005) 9.67
XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev (1999) 9.50
Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med (2003) 7.23
Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med (1996) 5.14
Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev (2002) 5.04
Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. EMBO J (1996) 4.89
Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci U S A (1994) 4.57
Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci (1998) 4.01
An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III. Mol Cell Biol (1994) 3.99
The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev (2005) 3.90
Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst (2000) 3.55
Cancer in Fanconi anemia, 1927-2001. Cancer (2003) 3.31
The role of double-strand break repair - insights from human genetics. Nat Rev Genet (2006) 3.25
Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res (1998) 2.93
Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica (2008) 2.72
Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol (1986) 2.64
Telomere dysfunction increases mutation rate and genomic instability. Cell (2001) 2.62
Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proc Natl Acad Sci U S A (1995) 2.48
Xrcc3 is required for assembly of Rad51 complexes in vivo. J Biol Chem (1998) 2.44
XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis (2001) 2.35
Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med (1991) 2.27
Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther (2004) 2.20
Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie (2003) 2.03
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood (2008) 1.98
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant (2007) 1.84
Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med (1991) 1.83
Malignant neoplasms following bone marrow transplantation. Blood (1996) 1.76
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood (2000) 1.74
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood (2009) 1.70
Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst (1995) 1.66
A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology (1995) 1.65
Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med (1999) 1.63
Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect (2003) 1.55
Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst (2000) 1.54
Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood (2002) 1.54
Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A (1998) 1.48
Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol (1996) 1.46
Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol (1999) 1.45
Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer Cell (2011) 1.44
Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol (2000) 1.39
Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci U S A (2001) 1.39
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica (2009) 1.34
Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst (1993) 1.34
Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res (2000) 1.31
Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci U S A (2000) 1.29
Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol (2009) 1.29
Fanconi anaemia and leukaemia - clinical and molecular aspects. Br J Haematol (2004) 1.26
Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists. Int J Cancer (2008) 1.26
Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol (1993) 1.23
Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood (1997) 1.23
Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res (2004) 1.20
When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol (1994) 1.19
Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood (1999) 1.18
Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood (2002) 1.18
Induction of cytochrome P4501A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin or indolo(3,2-b)carbazole is associated with oxidative DNA damage. Proc Natl Acad Sci U S A (1996) 1.17
The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood (2002) 1.16
Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry (2001) 1.16
Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer (2001) 1.14
Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol (1999) 1.13
Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood (2000) 1.13
Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res (1995) 1.11
Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists. Int J Cancer (2008) 1.10
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood (2004) 1.09
Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood (1996) 1.08
Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol (2001) 1.08
Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage. Am J Hematol (2007) 1.08
Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol (2007) 1.08
Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. J Clin Oncol (2005) 1.06
Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood (1998) 1.06
Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia (2005) 1.04
Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat Res (1996) 1.04
Repair of oxidative DNA damage: assessing its contribution to cancer prevention. Mutagenesis (2002) 1.02
An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res (2003) 1.02
Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia. Haematologica (1999) 0.98
The science of pharmacological variability: an essay. Clin Pharmacol Ther (1999) 0.98
Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. J Clin Oncol (2001) 0.98
Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Haematologica (1998) 0.95
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol (2013) 0.94
Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant (2003) 0.93
Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress. Blood (1994) 0.92
Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol (1998) 0.90
Breast cancer risk polymorphisms and interaction with ionizing radiation among U.S. radiologic technologists. Cancer Epidemiol Biomarkers Prev (2008) 0.90
Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. Biol Blood Marrow Transplant (2002) 0.88
Therapy-related acute leukemia. Clin Lab Med (2000) 0.87
Polymorphisms in human homeobox HLX1 and DNA repair RAD51 genes increase the risk of therapy-related acute myeloid leukemia. Blood (2006) 0.87
Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair (Amst) (2003) 0.86
Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood (1994) 0.86
Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia. Leukemia (2003) 0.84
Genetic susceptibility to therapy-related leukemia after Hodgkin lymphoma or non-Hodgkin lymphoma: role of drug metabolism, apoptosis and DNA repair. Blood Cancer J (2012) 0.83
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Leuk Lymphoma (2001) 0.81